Evaluating the usefulness of the estimated glomerular filtration rate for determination of imipenem dosage in critically ill patients
DOI:
https://doi.org/10.7196/SAMJ.2022.v112i9.16371Keywords:
Renal fuction, BacterialAbstract
Background. Antibiotic dosing in critically ill patients is complicated by variations in the pharmacokinetics of antibiotics in this group. The dosing of imipenem/cilastatin is usually determined by severity of illness and renal function.
Objectives. To determine the correlation between estimated glomerular filtration rates (eGFRs) calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and imipenem trough levels in critically ill patients.
Methods. This prospective observational study was done in the surgical intensive care unit (ICU) at Steve Biko Academic Hospital, Pretoria, South Africa. Imipenem trough levels were measured by high-performance liquid chromatography and compared with eGFRs calculated with the CKD-EPI equation. Correlation was evaluated by the Pearson product-moment correlation coefficient.
Results. The study population consisted of 68 critically ill patients aged between 18 and 81 years; 43 (63%) were male, and the mean weight was 78 kg (range 40 - 140). On admission, 30 patients (44%) had sepsis, 16 (24%) were admitted for trauma, and 22 (32%) were admitted for miscellaneous surgical conditions. Acute Physiology and Chronic Health Evaluation II (APACHE II) scores ranged from 4 to 39 (mean 18). The 28-day mortality rate was 29%. The mean albumin level was 16 g/L (range 7 - 25), the mean creatinine level 142 μmol/L (range 33 - 840), and the mean eGFR 91 mL/min/1.73 m2 (range 6 - 180). Imipenem trough levels ranged between 3.6 and 92.2 mg/L (mean 11.5). The unadjusted Pearson product-moment correlation coefficient between eGFR and imipenem trough level was –0.04 (p=0.761).
Conclusion. Considering the high mortality rate of sepsis in ICUs and the rapid global increase in antimicrobial resistance, it is crucial
to dose antibiotics appropriately. Owing to the variability of antibiotic pharmacokinetics in critically ill patients, this task becomes almost impossible when relying on conventional dosing guidelines. This study found that eGFRs do not correlate with imipenem blood levels in critically ill patients and should not be used to determine the dose of imipenem/cilastatin. Instead, the dose should be individualised for patients through routine therapeutic drug monitoring.
References
Fleischmann-Struzek C, Mellhammar L, Rose N, et al. Incidence and mortality of hospital- and ICU- treated sepsis: Results from an updated and expanded systematic review and meta-analysis. Intensive Care Med 2020;16(8):1552-1562. https://doi.org/10.1007/s00134-020-06151-x
Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34(6):1589-1596. https://doi.org/10.1097/01.CCM.0000217961.75225.E9
Roberts JA, Paul SK, Akova M, et al. DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014;58(8):1072-1083. https://doi.org/10.1093/cid/ciu027
Campion M, Scully G. Antibiotic use in the intensive care unit: Optimisation and de-escalation. J Intensive Care Med 2018;33(12):647-655. https://doi.org/10.1177/0885066618762747
Veiga RP, Paiva JA. Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta- lactam antibiotics in critically ill patients. Crit Care 2018;22(1):1-34. https://doi.org/10.1186/s13054- 018-2155-1
Heavner MS, Claeys KC, Masich AM, Gonzales JP. Pharmacokinetic and pharmacodynamic considerations of antibiotics of last resort in treating Gram-negative infections in adult critically ill patients. Curr Infect Dis Rep 2018;20(5):10. https://doi.org/10.1007/s11908-018-0614-0
Huttner A, Harbarth S, Hope WW, Lipman J, Roberts JA. Therapeutic drug monitoring of the β-lactam antibiotics: What is the evidence and which patients should we be using it for? J Antimicrob Chemother 2015;70(12):3178-3183. https://doi.org/10.1093/jac/dkv201
Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient – concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev 2014;77:3-11. https:// doi.org/10.1016/j.addr.2014.07.006
Buckley MM, Brogden RN, Barradell LB, Goa KL. Imipenem/cilastatin: A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1992;44(3):408-444. https://doi.org/10.2165/00003495-199244030-00008
Rodloff AC, Goldstein EJC, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006;58(5):916-929. https://doi.org/10.1093/jac/dkl354
Remschmidt C, Schneider S, Meyer E, Schroeren-Boersch B, Gastmeier P, Schwab F. Surveillance of antibiotic use and resistance in intensive care units (SARI): A 15-year cohort study. Dtsch Arztebl Int 2017;114(50):858-865. https://doi.org/10.3238/arztebl.2017.0858
Fluckiger U, Segessenmann C, Gerber AU. Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model. Antimicrob Agents Chemother 1991;35(9):1905-1910. https://doi.org/10.1128/AAC.35.9.1905
Yoshizawa K, Ikawa K, Ikeda K, Kumon H, Ohge H, Morikawa N. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data. Int J Antimicrob Agents 2012;40(5):427-433. https://doi.org/10.1016/j.ijantimicag.2008.08.031
Hayashi Y, Lipman J, Udy AA, et al. β-Lactam therapeutic drug monitoring in the critically ill: Optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. Int J Antimicrob Agents 2013;41(2):162-166. https://doi.org/10.1016/j.ijantimicag.2012.10.002
Abdul-Aziz MH, Alffenaar JW, Bassetti M, et al., on behalf of the Infection Section of European Society of Intensive Care Medicine (ESICM), Pharmacokinetic/Pharmacodynamic and Critically Ill Patient study groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) & Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: A position paper. Intensive Care Med 2020;46(6):1127-1153. https://doi.org/10.1007/ s00134-020-06050-1
Muller AE, Huttner B, Huttner A. Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: Which agents, which patients and which infections? Drugs 2018;78(4):439- 451. https://doi.org/10.1007/s40265-018-0880-z
Belzberg H, Zhu J, Cornwell EE, et al. Imipenem levels are not predictable in the critically ill patient. J Trauma 2004;56(1):111-117. https://doi.org/10.1097/01.TA.0000056164.26493.28
Imipenem [package insert]. Whitehouse Station, NJ: Merck & Co., 2007. https://www.sahpra.org.za/ wp-content/uploads/2020/02/Tienam_PI_MSD_MCC-format-13-May-2015.pdf (accessed 7 July 2021).
Lala M, Brown M, Kantesaria B, Walker B, Paschke A, Rizk ML. Simplification of imipenem dosing by removal of weight-based adjustments. J Clin Pharmacol 2019;59(5):646-653. https://doi.org/10.1002/
jcph.1356
Norrby SR, Björnegård B, Ferbert F, Jones KH. Pharmacokinetics of imipenem in healthy volunteers. J Antimicrob Chemother 1983;12(Suppl_D):109-124. https://doi.org/10.1093/jac/12.suppl_d.109
Rogers JD, Meisinger MA, Ferber F, Calandra GB, Demetriades JL, Bland JA. Pharmacokinetics
of imipenem and cilastatin in volunteers. Rev Infect Dis 1985;7(Suppl_3):S435-S446. https://doi.
org/10.1093/clinids/7.supplement_3.s435
Levey AS, Coresh J, Tighiouart H, Greene T, Inker LA. Measured and estimated glomerular filtration rate: Current status and future directions. Nat Rev Nephrol 2020;16(1):51-64. https://doi.org/10.1038/ s41581-019-0191-y
Miller WG, Jones GR. Estimated glomerular filtration rate: Laboratory implementation and current global status. Adv Chronic Kidney Dis 2018;25(1):7-13. https://doi.org/10.1053/j.ackd.2017.09.013
Al-Dorzi HM, Alsadhan AA, Almozaini AS, et al. The performance of equations that estimate
glomerular filtration rate against measured urinary creatinine clearance in critically ill patients. Crit
Care Res Pract 2021;2021:5520653. https://doi.org/10.1155/2021/5520653
Hudson JQ, Nolin TD. Pragmatic use of kidney function estimates for drug dosing: The tide is turning.
Adv Chronic Kidney Dis 2018;25(1):14-20. https://doi.org/10.1053/j.ackd.2017.10.003
Levey AS, Inker LA. Assessment of glomerular filtration rate in health and disease: A state of the art review. Clin Pharmacol Ther 2017;102(3):405-419. https://doi.org/10.1002/cpt.729
Elinder CG, Bárány P, Heimbürger O. The use of estimated glomerular filtration rate for dose adjustment of medications in the elderly. Drugs Aging 2014;31(7):493-499. https://doi.org/10.1007/ s40266-014-0187-z
Fournier A, Eggimann P, Pagani J, et al. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. Burns 2015;41(1):956- 968. https://doiorg/10.1016/j.burns.2015.01.001
Huttner A, Renzoni A, Pagani L, et al. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: An observational prospective cohort study. Int J Antimicrob Agents 2015;45(4):385-392. https://doi.org/10.1016/j.ijantimicag.2014.12.017
Sakka SG, Glauner AK, Bulitta JB, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomised, controlled trial. Antimicrob Agents Chemother 2007;51(9):3304-3310. https://doi.org/10.1128/ AAC.01318-06
Abhilash B, Tripathi CD, Gogia AR, Meshram GG, Kumar M, Suraj B. Pharmacokinetic/ pharmacodynamic profiling of imipenem in patients admitted to an intensive care unit in India: A nonrandomised, cross-sectional, analytical, open-labeled study. Indian J Crit Care Med 2015;19(10):587-592. https://doi.org/10.4103/0972-5229.167036
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150(9):604-612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985;13(10):818-829.
Garcia-Capdevila L, Lopez-Calull C, Arroyo C, Moral MA, Mangues MA, Bonal J. Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients. J Chromatogr B Biomed Sci Appl 1997;692(1):127-132. https://doi.org/10.1016/S0378- 4347(96)00498-7
Sime FB, Udy AA, Roberts JA. Augmented renal clearance in critically ill patients: Etiology, definition and implications for beta-lactam dose optimisation. Curr Opin Pharmacol 2015;24:1-6. https://doi. org/10.1016/j.coph.2015.06.002
Udy AA, Baptista JP, Lim NL, et al. Augmented renal clearance in the ICU: Results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations. Crit Care Med 2014;42(3):520-527. https://doi.org/10.1097/CCM.0000000000000029
McKindley DS, Boucher BA, Hess MM, Croce MA, Fabian TC. Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia. Pharmacotherapy 1996;16(5):924-931. https://doi. org/10.1002/j.1875-9114.1996.tb03010.x
Boucher BA, Hickerson WL, Kuhl DA, Bombassaro AM, Jaresko GS. Imipenem pharmacokinetics in patients with burns. Clin Pharmacol Ther 1990;48(2):130-137. https://doi.org/10.1038/clpt.1990.127
Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009;37(3):840-851; quiz 859. https://doi.org/10.1097/CCM.0b013e3181961bff
Fratoni AJ, Nicolau DP, Kuti JL. A guide to therapeutic drug monitoring of β‐lactam antibiotics. Pharmacotherapy 2021;41(2):220-233. https://doi.org/10.1002/phar.2505
Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams. Crit Care 2011;15(5):1-7. https://doi.org/10.1186/cc10441
Downloads
Published
Issue
Section
License
Copyright (c) 2022 B Mitton, F Paruk, A Gous, J Chausse, M Milne, P Becker, M Said
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
